1. |
Huang SP, Wu MS, Shun CT, et al. Cyclooxygenase2 increases hypoxiainducible factor1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma [J]. J Biomed Sci, 2005; 12(1)∶229.
|
2. |
Bae SH, Jung ES, Park YM, et al. Expression of cyclooxygenase2 (COX2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX2 inhibitor, NS398 [J]. Clin Cancer Res, 2001; 7(5)∶ 1410.
|
3. |
Fosslien E. Review: molecular pathology of cyclooxygenase2 in cancerinduced angiogenesis [J]. Ann Clin Lab Sci, 2001; 31(4)∶325.
|
4. |
Gallo O, Franchi A, Magnelli L, et al. Cyclooxygenase2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis [J]. Neoplasia, 2001; 3(1)∶53.
|
5. |
Leahy KM, Koki AT, Masferrer JL. Role of cyclooxygenases in angiogenesis [J]. Curr Med Chem, 2000; 7(11)∶1163.
|
6. |
Semenza GL. Targeting HIF1 for cancer therapy [J]. Nat Rev Cancer, 2003; 3(10)∶721.
|
7. |
丁磊, 陳孝平, 王海平. 肝癌和癌旁組織中HIF1α基因蛋白的表達及其臨床意義 [J]. 肝膽外科雜志, 2004; 12(1)∶32.
|
8. |
Blancher C, Moore JW , Talks KL, et al. Relationship of hypoxiainducible factor (HIF)1alpha and HIF2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines [J]. Cancer Res, 2000; 60(24)∶710.
|
9. |
Xu XC. COX2 inhibitors in cancer treatment and prevention, a recent development [J]. Anticancer Drugs, 2002; 13(2)∶127.
|
10. |
Yao M, Kargman S, Lam EC, et al. Inhibition of cyclooxygenase2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice [J]. Cancer Research, 2003; 63(3)∶ 586.
|
11. |
Abiru S, Nakao K, Ichikawa T, et al. Aspirin and NS398 inhibit hepatocyte growth factorinduced invasiveness of human hepatoma cells [J]. Hepatology, 2002; 35(5)∶1117.
|